

# Evolution Executive News: Avid Bioservices Announce New President & CEO

Avid Bioservices, a dedicated CDMO focused on the development and cGMP manufacturing of biopharmaceutical drug substances derived from mammalian cell culture, has named Nicholas Green as CEO and President.

Nicholas Green will succeed Rick Hancock who has served as interim president and CEO since May 2019, when Roger Lias departed after 17 months in the role. Mr Hancock will continue to serve on Avid's board of directors.



*Nicholas Green*

Mr. Green has more than 30 years of experience in the global pharmaceutical and healthcare services industry, with significant expertise in the contract manufacturing of novel pharmaceutical products. His global pharmaceutical experience spans across 4 continents, having run 31 facilities in nine countries covering North America, South America, Europe, and Asia. Green most recently served as president and CEO of Therapure Biopharma, where he oversaw the growth of the company's CDMO business, while also leading the creation of Therapure's proprietary plasma protein business, named Evolve. Prior to Therapure, he held a number of senior management roles, most notably acting as managing director for Nipa Laboratories Ltd. Other attained roles include acting as the head of the life science division of Clariant International Ltd (in the USA), becoming president and CEO of Rhodia Pharma Solutions Ltd. and also becoming president of Codexis (Inc.'s pharma division).

## Avid Bioservices Strategy

Having relaunched itself in 2018, Avid Bioservices says it is going from strength-to-strength in the contract manufacturing space and its strategy will continue with a new CEO.

Avid Bioservices emerged from drug developer 'Peregrine Pharmaceuticals' in January of 2018 as a contract development and manufacturing organization (CDMO). Previously, Avid were a product development organization, with manufacturing facilities to support the scale of their pipeline.

While they were focused on developing products, they were also offering services for process development and manufacturing. With their excess capacity, the decision was made to divest the entire portfolio of their pipeline and focus being Avid Bioservices, a dedicated CDMO. Avid is in "growth mode" and continuous assessment will be given to plans for an expansion at a 42,000 square-foot shell next to one of its facilities in Tustin.

Avid's business model is unlikely to change with the introduction of a new CEO. Avid have established themselves in the CDMO industry and, as such, have a respectable portfolio of specialised skills, as well as promising molecules at varying stages that they are currently working on. The company does not seek deviation and so plan to continue down the same pathway.

The logo for Avid Bioservices. The word 'AVID' is in a bold, red, sans-serif font. To its right is a stylized graphic element consisting of two overlapping, curved shapes in red and blue. Below this, the word 'BIOSERVICES' is written in a blue, sans-serif font.

# Avid Bioservices News

Avid recently announced a co-marketing agreement that will provide clients with an integrated “sequence-to-manufacturing” service. Under the terms of the non-exclusive agreement, the companies will offer customers Aragen’s cell line development expertise, integrated with Avid’s upstream and downstream process development and analytical services to drive efficiencies and reduce overall timelines for delivering CGMP bulk drug substances. This alliance aims to speed the entire CGMP manufacturing process by having a more compact team oversee a single, integrated project timeline with significant built-in process efficiencies.

**Joseph Carleone**, Chairman - board of directors, said, “On behalf of the Avid board, I’d like to welcome Nick as our new president and CEO. His appointment is the result of a deliberate and comprehensive search for an industry executive capable of leading Avid to achieve its full potential. Nick’s lengthy and impressive career in the pharmaceutical contract development and manufacturing sector, which has included senior leadership roles at several successful companies, positions him perfectly to oversee Avid’s ongoing efforts aimed at customer base expansion and revenue growth. The board and I look forward to the positive impact that Nick will make on the company’s business over both the near and long-term.”

**Nicholas Green:** “I am excited to join the Avid team and contribute my industry experience to helping the company continue its impressive growth trajectory,” said Mr. Green. “Today, there is significant and growing demand for companies at the leading edge of contract development and manufacturing services for biologics. With its high-quality offerings in the areas of process development, analytical services, and CGMP manufacturing, combined with its more than 25 years of experience in manufacturing complex biologics, Avid is among the best positioned companies to seize this opportunity.”

## About Avid Bioservices, Inc.

Avid Bioservices is a dedicated contract developer and manufacturing organization (CDMO) focused on the development and CGMP manufacturing of biopharmaceutical drug substances derived from mammalian cell culture. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With over 25 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs, the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of their services ranges from standalone process development projects to full development and manufacturing programs through commercialization.

**Source:** Avid Bioservices



**EVOLUTION**  
SEARCH PARTNERS

Evolution Search Partners are a boutique search firm operating globally across USA, Europe and APAC, providing ‘business critical’ teams to the Biomanufacturing and Cell Gene Therapy sector.

With 25 years acclaimed international Biotechnology experience, we offer strong global networks, exceptional technical and business acumen, and operate as an experienced, competent, trustworthy search partner.

**Online:** [www.evolutionexec.com](http://www.evolutionexec.com)

**Email:** [info@evolutionexec.com](mailto:info@evolutionexec.com)

**EVOLUTION**

[www.evolutionexec.com](http://www.evolutionexec.com)